NeoGenomics (NEO) Launches PTEN IHC CDx, Does The Valuation Still Look Full?

NeoGenomics (NEO) has drawn fresh attention after announcing FDA approval and the commercial launch of PTEN IHC CDx, an immunohistochemistry companion diagnostic for prostate adenocarcinoma patients with PTEN deficiency.

See our latest analysis for NeoGenomics.

The PTEN IHC CDx launch lands at a time when momentum in NeoGenomics’ stock has been building, with a 30.75% 1 month share price return and 77.70% 3 month share price return, while the 1 year total shareholder return of 109.84% contrasts with weaker 3 and 5 year total shareholder returns.

If this FDA approval has you looking at the wider opportunity in oncology and diagnostics, it could be worth checking a curated set of 40 healthcare AI stocks as a next step.

After such a sharp move and fresh FDA news, NeoGenomics now sits at a very different starting point for new money. Do the current fundamentals and price still provide enough potential return to justify the risks?

Most Popular Narrative: 3.7% Undervalued

NeoGenomics closed at $14.50, compared with a widely followed fair value estimate of $15.06 that is built on detailed revenue, margin and valuation assumptions.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Read the complete narrative.

Curious what has to happen for that fair value to stack up? The narrative leans on faster top line growth, rising margins and a premium earnings multiple tied to those targets.

Result: Fair Value of $15.06 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the bullish NeoGenomics narrative still faces pressure from declining nonclinical revenues and intense oncology testing competition, which could weigh on growth and margins.

Find out about the key risks to this NeoGenomics narrative.

Another View: NeoGenomics Looks Expensive On Sales

While the popular NeoGenomics narrative leans on a fair value of $15.06 and a 3.7% discount, the current P/S ratio of 2.5x is well above both the US Healthcare sector at 1.5x and an estimated fair ratio of 1.5x. That gap points to valuation risk rather than a clear bargain. Which signal do you think matters more?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With NeoGenomics sending mixed valuation signals, it makes sense to move quickly, review the underlying data yourself, and pressure test the story. To understand a key concern investors are watching, take a closer look at the 1 important warning sign.

Looking for more investment ideas beyond NeoGenomics?

If NeoGenomics has sharpened your focus on opportunities, do not stop here. Put that interest to work and uncover other stocks that may fit your style.

• Spot potential bargains early by checking a focused list of 47 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them yet.
• Strengthen your defense by scanning 78 resilient stocks with low risk scores built around companies with characteristics that may better withstand business and market shocks.
• Hunt for tomorrow's standouts before they attract broad attention by reviewing a screener containing 20 high quality undiscovered gems that filters for robust fundamentals hiding in plain sight.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com